HSV-2 Antibody (HSVA33): sc-51967

HSV-2 Antibody (HSVA33) is a mouse monoclonal IgG1 antibody that detects herpes simplex virus type 2 (HSV-2), with reactivity specific to the herpes simplex virus and is suitable for use in western blotting (WB) applications. HSV-2 is a significant pathogen known for its ability to establish lifelong latent infections within sensory ganglia, particularly residing in the sacral ganglion at the base of the spine, which is crucial for understanding its pathogenesis and potential for reactivation. The virus can remain dormant in nerve cells, leading to asymptomatic shedding, which is a major factor in transmission, as approximately 50% to 80% of new HSV-2 infections arise from individuals who do not exhibit any symptoms. The structure of HSV-2 is characterized by a large double-stranded DNA genome encased in an icosahedral nucleocapsid, surrounded by a lipid bilayer envelope, and an amorphous layer of proteins known as the tegument. This unique structural composition not only facilitates viral evasion of host immune response but also plays a critical role in viral lifecycle, including processes of reactivation and transmission. Anti-HSV-2 antibody (HSVA33) is an essential tool for researchers studying molecular mechanisms of HSV-2 infection and implications in human health.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

HSV-2 Antibody (HSVA33) References:

1. HSV-2 vaccine: current state and insights into development of a vaccine that targets genital mucosal protection.  |  Roth, K., et al. 2013. Microb Pathog. 58: 45-54. PMID: 23159485
2. HSV-2 vaccine: current status and insight into factors for developing an efficient vaccine.  |  Zhu, XP., et al. 2014. Viruses. 6: 371-90. PMID: 24469503
3. Biologic interactions between HSV-2 and HIV-1 and possible implications for HSV vaccine development.  |  Schiffer, JT. and Gottlieb, SL. 2019. Vaccine. 37: 7363-7371. PMID: 28958807
4. Development of a microneutralization assay for HSV-2.  |  Horton, MS., et al. 2021. J Virol Methods. 297: 114268. PMID: 34437874
5. Endogenous Retroviruses Provide Protection Against Vaginal HSV-2 Disease.  |  Jayewickreme, R., et al. 2021. Front Immunol. 12: 758721. PMID: 35058919
6. Migrasomes released by HSV-2-infected cells serve as a conveyance for virus spread.  |  Liu, Y., et al. 2023. Virol Sin. 38: 643-645. PMID: 37295496
7. A Trivalent HSV-2 gC2, gD2, gE2 Nucleoside-Modified mRNA-LNP Vaccine Provides Outstanding Protection in Mice against Genital and Non-Genital HSV-1 Infection, Comparable to the Same Antigens Derived from HSV-1.  |  Egan, KP., et al. 2023. Viruses. 15: PMID: 37515169
8. Boosting of vaginal HSV-2-specific B and T cell responses by intravaginal therapeutic immunization results in diminished recurrent HSV-2 disease.  |  Bourne, N., et al. 2023. J Virol. 97: e0066923. PMID: 37655939
9. HSV-2 Manipulates Autophagy through Interferon Pathway: A Strategy for Viral Survival.  |  Dass, D., et al. 2024. Viruses. 16: PMID: 39339859
10. Heparanase 2 Modulation Inhibits HSV-2 Replication by Regulating Heparan Sulfate.  |  Hopkins, J., et al. 2024. Viruses. 16: PMID: 39772142

The preferred HSV-1/2 ICP5 Major Capsid Protein antibody is HSV-1/2 ICP5 Major Capsid Protein Antibody (3B6): sc-56989.